548 related articles for article (PubMed ID: 23536636)
1. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.
Goding SR; Wilson KA; Xie Y; Harris KM; Baxi A; Akpinarli A; Fulton A; Tamada K; Strome SE; Antony PA
J Immunol; 2013 May; 190(9):4899-909. PubMed ID: 23536636
[TBL] [Abstract][Full Text] [Related]
2. PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4
Goding SR; Wilson KA; Rosinsky C; Antony PA
J Immunol; 2018 May; 200(9):3304-3311. PubMed ID: 29602773
[TBL] [Abstract][Full Text] [Related]
3. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.
Furtado R; Chorro L; Zimmerman N; Guillen E; Spaulding E; Chin SS; Daily JP; Lauvau G
Front Immunol; 2020; 11():576743. PubMed ID: 33519801
[TBL] [Abstract][Full Text] [Related]
4. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
5. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.
Wang W; Lau R; Yu D; Zhu W; Korman A; Weber J
Int Immunol; 2009 Sep; 21(9):1065-77. PubMed ID: 19651643
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
8. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma.
McGee HS; Yagita H; Shao Z; Agrawal DK
Am J Respir Cell Mol Biol; 2010 Oct; 43(4):432-42. PubMed ID: 19901343
[TBL] [Abstract][Full Text] [Related]
10. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.
Zhou Q; Munger ME; Highfill SL; Tolar J; Weigel BJ; Riddle M; Sharpe AH; Vallera DA; Azuma M; Levine BL; June CH; Murphy WJ; Munn DH; Blazar BR
Blood; 2010 Oct; 116(14):2484-93. PubMed ID: 20570856
[TBL] [Abstract][Full Text] [Related]
11. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.
Borkner L; Kaiser A; van de Kasteele W; Andreesen R; Mackensen A; Haanen JB; Schumacher TN; Blank C
Cancer Immunol Immunother; 2010 Aug; 59(8):1173-83. PubMed ID: 20349059
[TBL] [Abstract][Full Text] [Related]
12. Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.
Jensen SM; Twitty CG; Maston LD; Antony PA; Lim M; Hu HM; Petrausch U; Restifo NP; Fox BA
J Immunol; 2012 Jul; 189(2):767-76. PubMed ID: 22723522
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
14. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
[TBL] [Abstract][Full Text] [Related]
15. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.
Jacobs JF; Idema AJ; Bol KF; Nierkens S; Grauer OM; Wesseling P; Grotenhuis JA; Hoogerbrugge PM; de Vries IJ; Adema GJ
Neuro Oncol; 2009 Aug; 11(4):394-402. PubMed ID: 19028999
[TBL] [Abstract][Full Text] [Related]
17. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
Kearl TJ; Jing W; Gershan JA; Johnson BD
J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
[TBL] [Abstract][Full Text] [Related]
18. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
19. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Quezada SA; Peggs KS; Curran MA; Allison JP
J Clin Invest; 2006 Jul; 116(7):1935-45. PubMed ID: 16778987
[TBL] [Abstract][Full Text] [Related]
20. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.
Ghebeh H; Barhoush E; Tulbah A; Elkum N; Al-Tweigeri T; Dermime S
BMC Cancer; 2008 Feb; 8():57. PubMed ID: 18294387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
